AbbVie (ABBV) Stock Forecast & Price Target

AbbVie has demonstrated robust financial performance, with an increase in its global sales guidance for the Neuroscience segment to approximately $10.7 billion for 2025, reflecting growing momentum across key products such as Vyalev and Botox Therapeutic. Enhanced confidence in its financial outlook is further supported by the upward revision of the full-year 2025 EPS guidance to a range of $12.09-$12.29, bolstered by a $700 million increase in revenue expectations to about $59.7 billion. The strong quarterly sales of $13.34 billion, exceeding both company and consensus expectations, underline AbbVie's successful strategy in driving growth through its immunology and oncology franchises, positioning the company favorably for future performance.

The analysis of AbbVie's stock presents several fundamental concerns, notably the anticipated erosion of Humira's market share due to competitive biosimilars launching in 2025, which could adversely impact revenue projections. Additionally, the company's ability to penetrate the IBD market with key products such as Rinvoq and Skyrizi appears limited, hindering long-term growth expectations. Lastly, ongoing macroeconomic challenges, particularly affecting the Aesthetics segment, coupled with the risk of pipeline delays and clinical trial failures, cast further uncertainty on AbbVie's financial outlook.